|
Market Cap (24-Jun) $27,342,400 (1,032nd) |
Close (30-Jun) $0.008 |
Volume (30-Jun) 285,280 |
Shortsold (12-Dec) 6,497 (0.00%) (681st) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.09 |
EX1 released this announcement to the ASX on 7 October 2022, 8:17. The announcement is not marked as price sensitive, and is 43 page(s) in length and 16.48MB in size.
You can view all announcements from EX1 and see how they appear on a price chart on the announcements page.
At the date of this announcement, EX1 was 0.012% short sold according to ASIC data. It was ranked the 621st most shorted stock on the ASX. It remains ranked 681st as of the latest reported data (12 December 2022).
| Other Recent Announcements from EX1 | |
|---|---|
| Initial Director's Interest Notice - MD | 22 June 2023, 11:52 |
| Change of Director's Interest Notice - CB | 22 June 2023, 11:51 |
| Final Director's Interest Notice - JW | 22 June 2023, 11:50 |
| Investor Presentation | 7 October 2022, 8:17 |
| Study results indicate exosomes safe for clinical pursuit | 28 September 2022, 8:14 |
| Date of Annual General Meeting 2022 | 9 September 2022, 8:43 |
| FY2022 Appendix 4E and Annual Report | 31 August 2022, 8:08 |
You must be logged in to post a reply.
Exopharm 